Cover Image
市場調查報告書

細胞凋亡調節因子 BAX:開發中產品分析

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 516035
出版日期 內容資訊 英文 46 Pages
訂單完成後即時交付
價格
Back to Top
細胞凋亡調節因子 BAX:開發中產品分析 Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Pipeline Review, H2 2017
出版日期: 2017年11月28日 內容資訊: 英文 46 Pages
簡介

本報告提供以細胞凋亡調節因子 BAX為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

細胞凋亡調節因子 BAX;概要

細胞凋亡調節因子 BAX;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Genervon Biopharmaceuticals LLC
  • Huons Co Ltd
  • Lytix Biopharma AS

藥物簡介

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC1165TDB

Summary:

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Apoptosis regulator BAX or bcl-2-like protein 4 is a protein is encoded by the BAX gene. It accelerates programmed cell death by antagonizing the apoptosis repressor BCL2. It promotes activation of CASP3, and thereby apoptosis. It undergoes a conformation change that causes translocation to the mitochondrion membrane, leading to the release of cytochrome c that then triggers apoptosis under stress conditions.

Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) pipeline Target constitutes close to 7 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Central Nervous System which include indications Lung Cancer, Acute Ischemic Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyotrophic Lateral Sclerosis, Liver Cancer, Melanoma, Myocardial Infarction, Parkinson's Disease and Stroke.

The latest report Apoptosis Regulator BAX - Pipeline Review, H2 2017, outlays comprehensive information on the Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX)
  • The report reviews Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Overview
    • Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Companies Involved in Therapeutics Development
    • Genervon Biopharmaceuticals LLC
    • Huons Global Co Ltd
    • Lytix Biopharma AS
  • Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Drug Profiles
    • GM-6 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HU-010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LTX-401 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate Apoptosis Regulator BAX for Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate BAX for Acute Myelocytic Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BAX for Myocardial Infarction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SMBA-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Dormant Products
  • Apoptosis Regulator BAX (Bcl 2 Like Protein 4 or BCL2L4 or BAX) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 06, 2017: Lytix Biopharma presents poster on LTX-401 at AACR in Washington April 2017
      • Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published
      • Jan 10, 2017: Genervon Releases ALS, PD and AD Disease­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm
      • Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways
      • Sep 21, 2016: Lytix Biopharma develops second generation oncolytic molecules for deep seated tumors
      • Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS
      • May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604
      • May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe
      • Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression
      • Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease
      • Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA
      • Jan 08, 2015: Genervon Announces ALS Compassionate Use Results
      • Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results
      • Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS
      • Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Genervon Biopharmaceuticals LLC, H2 2017
  • Pipeline by Huons Global Co Ltd, H2 2017
  • Pipeline by Lytix Biopharma AS, H2 2017
  • Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top